CHO Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of innovative products based on the proprietary glycan engineering technologies. Its products include CHO-H01 & CHO-H02 antibody for cancer; CHO-H03 antibody for autoimmune disease; CHO-A04 antibody for cancer; CHO-S05 dual-effect anti-flu drug; and CHO-V07 glycan-based vaccines & drugs. The company was founded by Kong Ming Lu on March 8, 2013 and is headquartered in Nangang, Taiwan.